» Articles » PMID: 36846368

Site-directed Late-stage Diversification of Macrocyclic Nannocystins Facilitating Anticancer SAR and Mode of Action Studies

Overview
Journal RSC Med Chem
Specialty Chemistry
Date 2023 Feb 27
PMID 36846368
Authors
Affiliations
Soon will be listed here.
Abstract

Nannocystins are a family of 21-membered cyclodepsipeptides with excellent anticancer activity. However, their macrocyclic architecture poses a significant challenge to structure modification. Herein, this issue is addressed by leveraging the strategy of post-macrocyclization diversification. In particular, a novel serine-incorporating nannocystin was designed so that its appending hydroxyl group could diversify into a wide variety of side chain analogues. Such effort facilitated not only structure-activity correlation at the subdomain of interest, but also the development of a macrocyclic coumarin-labeled fluorescence probe. Uptake experiments indicated good cell permeability of the probe, and endoplasmic reticulum was identified as its subcellular localization site.

Citing Articles

Discovery of a nitroaromatic nannocystin with potent in vivo anticancer activity against colorectal cancer by targeting AKT1.

Zhang H, Xie F, Yuan X, Dai X, Tian Y, Sun M Acta Pharmacol Sin. 2024; 45(5):1044-1059.

PMID: 38326625 PMC: 11053100. DOI: 10.1038/s41401-024-01231-w.


Heck Macrocyclization in Forging Non-Natural Large Rings including Macrocyclic Drugs.

Cai J, Sun B, Yu S, Zhang H, Zhang W Int J Mol Sci. 2023; 24(9).

PMID: 37175956 PMC: 10179193. DOI: 10.3390/ijms24098252.


Anticancer Small-Molecule Agents Targeting Eukaryotic Elongation Factor 1A: State of the Art.

Zhang H, Cai J, Yu S, Sun B, Zhang W Int J Mol Sci. 2023; 24(6).

PMID: 36982256 PMC: 10049629. DOI: 10.3390/ijms24065184.

References
1.
Zhou Y, Yan B, Yang Q, Long X, Zhang D, Luo R . Harnessing Natural Products by a Pharmacophore-Oriented Semisynthesis Approach for the Discovery of Potential Anti-SARS-CoV-2 Agents. Angew Chem Int Ed Engl. 2022; 61(28):e202201684. PMC: 9074085. DOI: 10.1002/anie.202201684. View

2.
Vincent F, Nueda A, Lee J, Schenone M, Prunotto M, Mercola M . Phenotypic drug discovery: recent successes, lessons learned and new directions. Nat Rev Drug Discov. 2022; 21(12):899-914. PMC: 9708951. DOI: 10.1038/s41573-022-00472-w. View

3.
Marsault E, Peterson M . Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery. J Med Chem. 2011; 54(7):1961-2004. DOI: 10.1021/jm1012374. View

4.
Bowers A, West N, Newkirk T, Troutman-Youngman A, Schreiber S, Wiest O . Synthesis and histone deacetylase inhibitory activity of largazole analogs: alteration of the zinc-binding domain and macrocyclic scaffold. Org Lett. 2009; 11(6):1301-4. PMC: 2673910. DOI: 10.1021/ol900078k. View

5.
Ying Y, Liu Y, Byeon S, Kim H, Luesch H, Hong J . Synthesis and activity of largazole analogues with linker and macrocycle modification. Org Lett. 2008; 10(18):4021-4. DOI: 10.1021/ol801532s. View